home / stock / glaxf / glaxf news


GLAXF News and Press, GlaxoSmithKline Plc From 04/25/24

Stock Information

Company Name: GlaxoSmithKline Plc
Stock Symbol: GLAXF
Market: OTC
Website: gsk.com

Menu

GLAXF GLAXF Quote GLAXF Short GLAXF News GLAXF Articles GLAXF Message Board
Get GLAXF Alerts

News, Short Squeeze, Breakout and More Instantly...

GLAXF - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

GLAXF - Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

2024-04-23 11:37:17 ET Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from ...

GLAXF - GSK Trades At Low Price Multiples, But Its Pipeline Needs To Improve

2024-04-19 04:02:55 ET Summary GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate the effectiveness and efficiency of its pipelin...

GLAXF - International Wide-Moat Stocks On Sale - The April 2024 Heat Map

2024-04-17 01:50:40 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

GLAXF - Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

2024-04-16 18:25:52 ET Summary Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results ...

GLAXF - VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

GLAXF - Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

2024-04-12 14:12:23 ET Summary Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with...

GLAXF - Aristotle Capital International Equity Q1 2024 Commentary

2024-04-11 10:40:00 ET Summary Aristotle Capital Management is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide. or the first quarter of 2024, Aristotl...

GLAXF - GSK plc (GSK) TD Cowen 44th Annual Health Care Conference (Transcript)

2024-03-11 12:54:07 ET GSK plc (GSK) TD Cowen 44th Annual Health Care Conference March 4, 2024, 2:50 pm ET Company Participants Luke Miels - CCO Conference Call Participants Stephen Scala - TD Cowen Presentation Stephen Scala Well, good af...

GLAXF - International Wide-Moat Stocks On Sale - The March 2024 Heat Map

2024-03-11 08:22:37 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

Previous 10 Next 10